ELANCO ANIMAL HEALTH INC (ELAN) Stock Fundamental Analysis

NYSE:ELAN • US28414H1032

26.4 USD
+0.21 (+0.8%)
At close: Feb 27, 2026
26.46 USD
+0.06 (+0.23%)
After Hours: 2/27/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Taking everything into account, ELAN scores 4 out of 10 in our fundamental rating. ELAN was compared to 192 industry peers in the Pharmaceuticals industry. ELAN has only an average score on both its financial health and profitability. ELAN has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • In the past year ELAN was profitable.
  • ELAN had a positive operating cash flow in the past year.
  • In the past 5 years ELAN reported 4 times negative net income.
  • ELAN had a positive operating cash flow in 4 of the past 5 years.
ELAN Yearly Net Income VS EBIT VS OCF VS FCFELAN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M -1B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 0.27%, ELAN is in the better half of the industry, outperforming 78.65% of the companies in the same industry.
  • With an excellent Return On Equity value of 0.53%, ELAN belongs to the best of the industry, outperforming 80.21% of the companies in the same industry.
  • With a decent Return On Invested Capital value of 1.38%, ELAN is doing good in the industry, outperforming 78.65% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for ELAN is significantly below the industry average of 12.96%.
Industry RankSector Rank
ROA 0.27%
ROE 0.53%
ROIC 1.38%
ROA(3y)-2.13%
ROA(5y)-2.51%
ROE(3y)-5.1%
ROE(5y)-5.7%
ROIC(3y)1.73%
ROIC(5y)N/A
ELAN Yearly ROA, ROE, ROICELAN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 -10 -15

1.3 Margins

  • Looking at the Profit Margin, with a value of 0.78%, ELAN is in the better half of the industry, outperforming 78.65% of the companies in the same industry.
  • In the last couple of years the Profit Margin of ELAN has grown nicely.
  • ELAN's Operating Margin of 5.25% is fine compared to the rest of the industry. ELAN outperforms 79.69% of its industry peers.
  • In the last couple of years the Operating Margin of ELAN has declined.
  • ELAN has a Gross Margin of 54.96%. This is in the better half of the industry: ELAN outperforms 67.71% of its industry peers.
  • ELAN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 5.25%
PM (TTM) 0.78%
GM 54.96%
OM growth 3Y-3.95%
OM growth 5Y-14.04%
PM growth 3YN/A
PM growth 5Y28.06%
GM growth 3Y-0.22%
GM growth 5Y1.04%
ELAN Yearly Profit, Operating, Gross MarginsELAN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ELAN is destroying value.
  • ELAN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ELAN Yearly Shares OutstandingELAN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
ELAN Yearly Total Debt VS Total AssetsELAN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

  • Based on the Altman-Z score of 1.53, we must say that ELAN is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of 1.53, ELAN perfoms like the industry average, outperforming 59.90% of the companies in the same industry.
  • ELAN has a debt to FCF ratio of 11.12. This is a negative value and a sign of low solvency as ELAN would need 11.12 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 11.12, ELAN belongs to the top of the industry, outperforming 80.73% of the companies in the same industry.
  • A Debt/Equity ratio of 0.59 indicates that ELAN is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.59, ELAN is not doing good in the industry: 65.63% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.59
Debt/FCF 11.12
Altman-Z 1.53
ROIC/WACC0.16
WACC8.58%
ELAN Yearly LT Debt VS Equity VS FCFELAN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B 8B

2.3 Liquidity

  • A Current Ratio of 2.40 indicates that ELAN has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 2.40, ELAN is in line with its industry, outperforming 43.75% of the companies in the same industry.
  • ELAN has a Quick Ratio of 1.23. This is a normal value and indicates that ELAN is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of ELAN (1.23) is worse than 70.83% of its industry peers.
Industry RankSector Rank
Current Ratio 2.4
Quick Ratio 1.23
ELAN Yearly Current Assets VS Current LiabilitesELAN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • ELAN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.40%.
  • Measured over the past years, ELAN shows a quite strong growth in Earnings Per Share. The EPS has been growing by 15.11% on average per year.
EPS 1Y (TTM)4.4%
EPS 3Y-5.06%
EPS 5Y15.11%
EPS Q2Q%-7.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%12.16%

3.2 Future

  • The Earnings Per Share is expected to grow by 10.51% on average over the next years. This is quite good.
  • Based on estimates for the next years, ELAN will show a small growth in Revenue. The Revenue will grow by 4.39% on average per year.
EPS Next Y10.05%
EPS Next 2Y11.47%
EPS Next 3Y13.05%
EPS Next 5Y10.51%
Revenue Next Year5.8%
Revenue Next 2Y5.53%
Revenue Next 3Y5.12%
Revenue Next 5Y4.39%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ELAN Yearly Revenue VS EstimatesELAN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2B 4B 6B
ELAN Yearly EPS VS EstimatesELAN Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 27.79 indicates a quite expensive valuation of ELAN.
  • Based on the Price/Earnings ratio, ELAN is valued a bit cheaper than 79.17% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.10. ELAN is around the same levels.
  • The Price/Forward Earnings ratio is 25.25, which means the current valuation is very expensive for ELAN.
  • ELAN's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. ELAN is cheaper than 75.00% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.06, ELAN is valued at the same level.
Industry RankSector Rank
PE 27.79
Fwd PE 25.25
ELAN Price Earnings VS Forward Price EarningsELAN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ELAN is valued cheaper than 81.25% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of ELAN indicates a rather cheap valuation: ELAN is cheaper than 80.21% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 36.24
EV/EBITDA 18.15
ELAN Per share dataELAN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ELAN does not grow enough to justify the current Price/Earnings ratio.
  • ELAN's earnings are expected to grow with 13.05% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.76
PEG (5Y)1.84
EPS Next 2Y11.47%
EPS Next 3Y13.05%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ELAN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ELANCO ANIMAL HEALTH INC

NYSE:ELAN (2/27/2026, 8:04:00 PM)

After market: 26.46 +0.06 (+0.23%)

26.4

+0.21 (+0.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-24
Earnings (Next)05-05
Inst Owners116.54%
Inst Owner Change-10.48%
Ins Owners0.99%
Ins Owner Change4.72%
Market Cap13.12B
Revenue(TTM)N/A
Net Income(TTM)36.00M
Analysts85.45
Price Target27.2 (3.03%)
Short Float %4.73%
Short Ratio4.49
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.7%
Min EPS beat(2)30.48%
Max EPS beat(2)42.93%
EPS beat(4)3
Avg EPS beat(4)20.43%
Min EPS beat(4)-8.7%
Max EPS beat(4)42.93%
EPS beat(8)6
Avg EPS beat(8)14.04%
EPS beat(12)10
Avg EPS beat(12)44.02%
EPS beat(16)13
Avg EPS beat(16)38.17%
Revenue beat(2)2
Avg Revenue beat(2)2.27%
Min Revenue beat(2)2.06%
Max Revenue beat(2)2.48%
Revenue beat(4)3
Avg Revenue beat(4)0.91%
Min Revenue beat(4)-0.97%
Max Revenue beat(4)2.48%
Revenue beat(8)6
Avg Revenue beat(8)0.5%
Revenue beat(12)9
Avg Revenue beat(12)0.62%
Revenue beat(16)9
Avg Revenue beat(16)-0.02%
PT rev (1m)3.61%
PT rev (3m)10.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.19%
EPS NY rev (1m)0%
EPS NY rev (3m)3.77%
Revenue NQ rev (1m)0.09%
Revenue NQ rev (3m)0.09%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.41%
Valuation
Industry RankSector Rank
PE 27.79
Fwd PE 25.25
P/S 2.86
P/FCF 36.24
P/OCF 20.85
P/B 1.94
P/tB N/A
EV/EBITDA 18.15
EPS(TTM)0.95
EY3.6%
EPS(NY)1.05
Fwd EY3.96%
FCF(TTM)0.73
FCFY2.76%
OCF(TTM)1.27
OCFY4.8%
SpS9.24
BVpS13.58
TBVpS-3.24
PEG (NY)2.76
PEG (5Y)1.84
Graham Number17.04
Profitability
Industry RankSector Rank
ROA 0.27%
ROE 0.53%
ROCE 1.99%
ROIC 1.38%
ROICexc 1.44%
ROICexgc 5.17%
OM 5.25%
PM (TTM) 0.78%
GM 54.96%
FCFM 7.88%
ROA(3y)-2.13%
ROA(5y)-2.51%
ROE(3y)-5.1%
ROE(5y)-5.7%
ROIC(3y)1.73%
ROIC(5y)N/A
ROICexc(3y)1.78%
ROICexc(5y)N/A
ROICexgc(3y)7.88%
ROICexgc(5y)N/A
ROCE(3y)2.5%
ROCE(5y)N/A
ROICexgc growth 3Y-9.66%
ROICexgc growth 5Y-10.16%
ROICexc growth 3Y2.68%
ROICexc growth 5Y-13.27%
OM growth 3Y-3.95%
OM growth 5Y-14.04%
PM growth 3YN/A
PM growth 5Y28.06%
GM growth 3Y-0.22%
GM growth 5Y1.04%
F-Score6
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.59
Debt/FCF 11.12
Debt/EBITDA 4.35
Cap/Depr 39.85%
Cap/Sales 5.82%
Interest Coverage 250
Cash Conversion 69.05%
Profit Quality 1005.56%
Current Ratio 2.4
Quick Ratio 1.23
Altman-Z 1.53
F-Score6
WACC8.58%
ROIC/WACC0.16
Cap/Depr(3y)24.5%
Cap/Depr(5y)32.23%
Cap/Sales(3y)3.76%
Cap/Sales(5y)4.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.4%
EPS 3Y-5.06%
EPS 5Y15.11%
EPS Q2Q%-7.14%
EPS Next Y10.05%
EPS Next 2Y11.47%
EPS Next 3Y13.05%
EPS Next 5Y10.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%12.16%
Revenue Next Year5.8%
Revenue Next 2Y5.53%
Revenue Next 3Y5.12%
Revenue Next 5Y4.39%
EBIT growth 1Y-4.74%
EBIT growth 3Y-6.19%
EBIT growth 5Y-7.47%
EBIT Next Year19.46%
EBIT Next 3Y12.44%
EBIT Next 5Y9.88%
FCF growth 1Y656.92%
FCF growth 3Y9.94%
FCF growth 5Y70.08%
OCF growth 1Y395.28%
OCF growth 3Y3.85%
OCF growth 5Y19.28%

ELANCO ANIMAL HEALTH INC / ELAN FAQ

What is the ChartMill fundamental rating of ELANCO ANIMAL HEALTH INC (ELAN) stock?

ChartMill assigns a fundamental rating of 4 / 10 to ELAN.


Can you provide the valuation status for ELANCO ANIMAL HEALTH INC?

ChartMill assigns a valuation rating of 4 / 10 to ELANCO ANIMAL HEALTH INC (ELAN). This can be considered as Fairly Valued.


Can you provide the profitability details for ELANCO ANIMAL HEALTH INC?

ELANCO ANIMAL HEALTH INC (ELAN) has a profitability rating of 5 / 10.


Can you provide the financial health for ELAN stock?

The financial health rating of ELANCO ANIMAL HEALTH INC (ELAN) is 4 / 10.


Can you provide the expected EPS growth for ELAN stock?

The Earnings per Share (EPS) of ELANCO ANIMAL HEALTH INC (ELAN) is expected to grow by 10.05% in the next year.